Stay updated on Fremanezumab Subq for Migraine Preven Clinical Trial

Sign up to get notified when there's something new on the Fremanezumab Subq for Migraine Preven Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fremanezumab Subq for Migraine Preven Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update or modification in the context of medical and healthcare-related publications and documentation.
    Difference
    0.1%
    Check dated 2024-06-06T14:42:27.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for participants, including specific health conditions and prior treatments required for inclusion. The new criteria outline requirements for both participants rolling over from pivotal efficacy studies and new participants, emphasizing informed consent and specific health metrics.
    Difference
    22%
    Check dated 2024-05-22T21:32:47.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:47:42.000Z thumbnail image

Stay in the know with updates to Fremanezumab Subq for Migraine Preven Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fremanezumab Subq for Migraine Preven Clinical Trial page.